Nonalcoholic fatty liver disease（NAFLD）with high heterogeneity of its pathogenesis is closely associated with obesity，metabolic disorders and cardiovascular diseases. Moreover，nonalcoholic steatohepatitis （NASH）is at the increasing risks of progressing to liver fibrosis ，cirrhosis，end⁃stage liver disease and even hepatocellular carcinoma（HCC）. So far，neither the European drug administration nor the U.S. Food and Drug Administration（FDA）has approved any drugs for the management of NAFLD. The research and development of therapeutic drugs has always been a hot spot. In recent years，a large number of potential targeted drugs with clinical application prospects have emerged. This paper reviews the latest data on the main pharmacological targets of NAFLD.